{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:53:13Z","timestamp":1792036393299,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/leu.2017.182","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T06:40:28Z","timestamp":1496817628000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Nucleotide excision repair is a potential therapeutic target in multiple myeloma"],"prefix":"10.1038","volume":"32","author":[{"given":"R","family":"Szalat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Nanjappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Cleynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Calkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Reznichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-T","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Shammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Fermand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-B","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"BFleu2017182_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE . The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335\u2013348.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017182_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28: 981\u2013992.","journal-title":"Leukemia"},{"key":"BFleu2017182_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","volume":"12","author":"NJ Curtin","year":"2012","unstructured":"Curtin NJ . DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12: 801\u2013817.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017182_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrc3185","volume":"12","author":"D Fu","year":"2012","unstructured":"Fu D, Calvo JA, Samson LD . Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012; 12: 104\u2013120.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017182_CR5","first-page":"5196","volume":"58","author":"DF Grant","year":"1998","unstructured":"Grant DF, Bessho T, Reardon JT . Nucleotide excision repair of melphalan monoadducts. Cancer Res 1998; 58: 5196\u20135200.","journal-title":"Cancer Res"},{"key":"BFleu2017182_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/1471-2407-12-436","volume":"12","author":"VJ Spanswick","year":"2012","unstructured":"Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K et al. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer 2012; 12: 436.","journal-title":"BMC Cancer"},{"key":"BFleu2017182_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.V100.1.224","volume":"100","author":"VJ Spanswick","year":"2002","unstructured":"Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100: 224\u2013229.","journal-title":"Blood"},{"key":"BFleu2017182_CR8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","volume":"106","author":"Q Chen","year":"2005","unstructured":"Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS . The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106: 698\u2013705.","journal-title":"Blood"},{"key":"BFleu2017182_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/15384047.2015.1040951","volume":"16","author":"DA Alagpulinsa","year":"2015","unstructured":"Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ . A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment. Cancer Biol Ther 2015; 16: 976\u2013986.","journal-title":"Cancer Biol Ther"},{"key":"BFleu2017182_CR10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/bjc.2014.410","volume":"111","author":"M Gkotzamanidou","year":"2014","unstructured":"Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, Souliotis VL . Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. Br J Cancer 2014; 111: 1293\u20131304.","journal-title":"Br J Cancer"},{"key":"BFleu2017182_CR11","doi-asserted-by":"publisher","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-09-2616","volume":"69","author":"DN Yarde","year":"2009","unstructured":"Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D et al. Targeting the Fanconi anemia\/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009; 69: 9367\u20139375.","journal-title":"Cancer Res"},{"key":"BFleu2017182_CR12","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1038\/bcj.2014.45","volume":"4","author":"A Tagde","year":"2014","unstructured":"Tagde A, Singh H, Kang MH, Reynolds CP . The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 2014; 4: e229.","journal-title":"Blood Cancer J"},{"key":"BFleu2017182_CR13","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00018-015-1859-5","volume":"72","author":"S Alekseev","year":"2015","unstructured":"Alekseev S, Coin F . Orchestral maneuvers at the damaged sites in nucleotide excision repair. Cell Mol Life Sci 2015; 72: 2177\u20132186.","journal-title":"Cell Mol Life Sci"},{"key":"BFleu2017182_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.tig.2012.06.004","volume":"28","author":"I Kamileri","year":"2012","unstructured":"Kamileri I, Karakasilioti I, Garinis GA . Nucleotide excision repair: new tricks with old bricks. Trends Genet 2012; 28: 566\u2013573.","journal-title":"Trends Genet"},{"key":"BFleu2017182_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Tiao G et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 2016; 48: 600\u2013606.","journal-title":"Nat Genet"},{"key":"BFleu2017182_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","volume":"75","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015; 75: 628\u2013634.","journal-title":"Cancer Res"},{"key":"BFleu2017182_CR17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2159-8290.CD-16-0487","volume":"6","author":"J Vijai","year":"2016","unstructured":"Vijai J, Topka S, Villano D, Ravichandran V, Maxwell KN, Maria A et al. A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer Discov 2016; 6: 1267\u20131275.","journal-title":"Cancer Discov"},{"key":"BFleu2017182_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood-2007-05-088674","volume":"111","author":"J Lauring","year":"2008","unstructured":"Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008; 111: 856\u2013864.","journal-title":"Blood"},{"key":"BFleu2017182_CR19","doi-asserted-by":"publisher","first-page":"e85896","DOI":"10.1371\/journal.pone.0085896","volume":"9","author":"M Dreze","year":"2014","unstructured":"Dreze M, Calkins AS, Galicza J, Echelman DJ, Schnorenberg MR, Fell GL et al. Monitoring repair of UV-induced 6-4-photoproducts with a purified DDB2 protein complex. PLoS One 2014; 9: e85896.","journal-title":"PLoS One"},{"key":"BFleu2017182_CR20","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006; 7: R100.","journal-title":"Genome Biol"},{"key":"BFleu2017182_CR21","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1182\/blood-2014-04-569327","volume":"124","author":"NU Rashid","year":"2014","unstructured":"Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT et al. Differential and limited expression of mutant alleles in multiple myeloma. Blood 2014; 124: 3110\u20133117.","journal-title":"Blood"},{"key":"BFleu2017182_CR22","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","volume":"13","author":"AJ Pierce","year":"1999","unstructured":"Pierce AJ, Johnson RD, Thompson LH, Jasin M . XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999; 13: 2633\u20132638.","journal-title":"Genes Dev"},{"key":"BFleu2017182_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91\u2013101.","journal-title":"Cancer Cell"},{"key":"BFleu2017182_CR24","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.","journal-title":"Nat Commun"},{"key":"BFleu2017182_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","volume":"21","author":"S Alekseev","year":"2014","unstructured":"Alekseev S, Ayadi M, Brino L, Egly JM, Larsen AK, Coin F . A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum. Chem Biol 2014; 21: 398\u2013407.","journal-title":"Chem Biol"},{"key":"BFleu2017182_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nchembio.522","volume":"7","author":"DV Titov","year":"2011","unstructured":"Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011; 7: 182\u2013188.","journal-title":"Nat Chem Biol"},{"key":"BFleu2017182_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.molcel.2017.01.012","volume":"65","author":"S Alekseev","year":"2017","unstructured":"Alekseev S, Nagy Z, Sandoz J, Weiss A, Egly JM, Le May N et al. Transcription without XPB establishes a unified helicase-independent mechanism of promoter opening in eukaryotic gene expression. Mol Cell 2017; 65: 504\u2013514. e504.","journal-title":"Mol Cell"},{"key":"BFleu2017182_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2014.07.001","volume":"28","author":"C Varga","year":"2014","unstructured":"Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC, Richardson PG . Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin N Am 2014; 28: 903\u2013925.","journal-title":"Hematol Oncol Clin N Am"},{"key":"BFleu2017182_CR29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","volume":"126","author":"M Attal","year":"2015","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial). Blood 2015; 126: 391\u2013391.","journal-title":"Blood"},{"key":"BFleu2017182_CR30","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.4161\/cc.25951","volume":"12","author":"C Gourzones-Dmitriev","year":"2013","unstructured":"Gourzones-Dmitriev C, Kassambara A, Sahota S, Reme T, Moreaux J, Bourquard P et al. DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle 2013; 12: 2760\u20132773.","journal-title":"Cell Cycle"},{"key":"BFleu2017182_CR31","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","volume":"113","author":"MA Shammas","year":"2009","unstructured":"Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC . Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009; 113: 2290\u20132297.","journal-title":"Blood"},{"key":"BFleu2017182_CR32","doi-asserted-by":"publisher","first-page":"e0121581","DOI":"10.1371\/journal.pone.0121581","volume":"10","author":"AB Herrero","year":"2015","unstructured":"Herrero AB, San Miguel J, Gutierrez NC . Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability. PLoS One 2015; 10: e0121581.","journal-title":"PLoS One"},{"key":"BFleu2017182_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nm.3562","volume":"20","author":"F Cottini","year":"2014","unstructured":"Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med 2014; 20: 599\u2013606.","journal-title":"Nat Med"},{"key":"BFleu2017182_CR34","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.dnarep.2006.05.006","volume":"5","author":"VL Souliotis","year":"2006","unstructured":"Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP . Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Rep 2006; 5: 972\u2013985.","journal-title":"DNA Rep"},{"key":"BFleu2017182_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269\u2013277.","journal-title":"Leukemia"},{"key":"BFleu2017182_CR36","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1038\/onc.2016.116","volume":"35","author":"MY Shah","year":"2016","unstructured":"Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, Ezponda T et al. MMSET\/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene 2016; 35: 5905\u20135915.","journal-title":"Oncogene"},{"key":"BFleu2017182_CR37","doi-asserted-by":"publisher","first-page":"e1004566","DOI":"10.1371\/journal.pgen.1004566","volume":"10","author":"R Popovic","year":"2014","unstructured":"Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Ezponda T, Shah MY et al. Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 2014; 10: e1004566.","journal-title":"PLoS Genet"},{"key":"BFleu2017182_CR38","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.leu.2404832","volume":"21","author":"P Moreau","year":"2007","unstructured":"Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007; 21: 2020\u20132024.","journal-title":"Leukemia"},{"key":"BFleu2017182_CR39","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2016-01-691618","volume":"128","author":"M Gkotzamanidou","year":"2016","unstructured":"Gkotzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, Souliotis VL . DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood 2016; 128: 1214\u20131225.","journal-title":"Blood"},{"key":"BFleu2017182_CR40","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","volume":"19","author":"D Chauhan","year":"2013","unstructured":"Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res 2013; 19: 3019\u20133031.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017182_CR41","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","volume":"118","author":"P Neri","year":"2011","unstructured":"Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A et al. Bortezomib-induced 'BRCAness' sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011; 118: 6368\u20136379.","journal-title":"Blood"},{"key":"BFleu2017182_CR42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3892\/ijo.2014.2280","volume":"44","author":"T Nakazato","year":"2014","unstructured":"Nakazato T, Sagawa M, Kizaki M . Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1. Int J Oncol 2014; 44: 1131\u20131138.","journal-title":"Int J Oncol"},{"key":"BFleu2017182_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjh.12164","volume":"160","author":"T Heimberger","year":"2013","unstructured":"Heimberger T, Andrulis M, Riedel S, Stuhmer T, Schraud H, Beilhack A et al. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol 2013; 160: 465\u2013476.","journal-title":"Br J Haematol"},{"key":"BFleu2017182_CR44","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3109\/10428194.2011.638069","volume":"53","author":"X Huang","year":"2012","unstructured":"Huang X, Yang M, Jin J . Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs. Leuk Lymphoma 2012; 53: 1188\u20131195.","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017182","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:07:57Z","timestamp":1684433277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFleu2017182"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.182","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]},"assertion":[{"value":"6 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}